About Celsee Diagnostics
Celsee Diagnostics is a company based in Plymouth (United States) founded in 2011 was acquired by Bio Rad in April 2020. Celsee Diagnostics has raised $40.43 million across 14 funding rounds from investors including Bio Rad and Ann Arbor SPARK. The company has 18 employees as of December 31, 2017. Celsee Diagnostics operates in a competitive market with competitors including Guardant Health, GRAIL, Natera, Foundation Medicine and ArcherDX, among others.
- Headquarter Plymouth, United States
- Employees 18 as on 31 Dec, 2017
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Celsee Diagnostics
Celsee Diagnostics has successfully raised a total of $40.43M across 14 strategic funding rounds. The most recent funding activity was a Series B round of $5.11 million completed in December 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Celsee Diagnostics
Celsee Diagnostics has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Bio Rad and Ann Arbor SPARK.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Portfolio of products and services for life science research and clinical diagnostic markets
|
Locked | Locked | Locked |
Investor details for Celsee Diagnostics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Celsee Diagnostics
Investment portfolio details for Celsee Diagnostics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Celsee Diagnostics
Detailed financials for Celsee Diagnostics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Celsee Diagnostics Comparisons
Peer comparison for Celsee Diagnostics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Celsee Diagnostics
Celsee Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, GRAIL, Natera, Foundation Medicine and ArcherDX, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Circulating tumor DNA is screened for early cancer detection.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Health risks are identified through online genetic and diagnostic testing.
|
Detailed competitors of Celsee Diagnostics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Celsee Diagnostics
Complete news archive for Celsee Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Celsee Diagnostics
Celsee Diagnostics was founded in 2011.
Celsee Diagnostics is headquartered in Plymouth, United States. It is registered at Plymouth, Massachusetts, United States.
Celsee Diagnostics is a funded company, having raised a total of $40.43M across 14 funding rounds to date.
As of Dec 31, 2017, the latest employee count at Celsee Diagnostics is 18.
Founded in 2011 and based in Plymouth, United States, Celsee Diagnostics operates in the biotechnology sector. An instrument system and reagent kit are offered by the company for the separation, detection, and retrieval of circulating tumor cells from peripheral whole blood. This approach serves as an alternative to invasive biopsies, utilizing microfluidic chips to capture rare cancer cells and support downstream molecular analysis for research purposes.
Celsee Diagnostics's top competitors include Guardant Health, GRAIL and Foundation Medicine.
Celsee Diagnostics has 2 investors. Key investors include Bio Rad, and Ann Arbor SPARK.